Statins in Cerebral Blood Flow & Neuronal Activity--A Pilot Study

Status Completed

Clinical Trial Summary

Specific Aim: Demonstrate that statins have an effect on cerebral blood flow and neuronal activity

Clinical Trial Description

A number of recent of recent studies suggests that statins, typically used to lower blood cholesterol have an effect on the brain. Patients treated with statins may have increased blood flow in the brain resulting in increased activity of the brain's neurons. The neuronal system is linked to memory. Brain magnetic resonance imaging (MRI) with magnetic resonance spectroscopy (MRS) and magnetic resonance perfusion (MRP) will be used to assess changes in neuronal activity in patients receiving statins vs. patients not receiving statins.

This is a single-site non-randomized pilot study. The study will include twenty (20), healthy consenting patients between the ages of 45 and 65 who are candidates for statin therapy as determined by their cardiologist(s). Two imaging visits will be required, one magnetic resonance imaging with Magnetic Resonance Spectroscopy and Magnetic Resonance Perfusion at baseline and one magnetic resonance imaging with magnetic resonance Spectroscopy and Magnetic Resonance Perfusion three months later as described.

Patients will have selected their course of clinical treatment prior to recruitment. Ten patients will have elected to start statin therapy with Lipitor and ten patients will have elected to initially lower their cholesterol levels with diet, independent of their participation in the study.

Participants on the "statin arm" will receive a dose of 20 mg per day of Lipitor and will receive a baseline brain Magnetic Resonance Imaging with Magnetic Resonance Spectroscopy and Magnetic Resonance Perfusion prior to receiving Lipitor and follow-up brain Magnetic Resonance Imaging with Magnetic Resonance Spectroscopy and Magnetic Resonance Perfusion three months after beginning Lipitor.

Participants on the "diet arm" will receive a baseline brain magnetic resonance imaging with Magnetic Resonance Spectroscopy and Magnetic Resonance Perfusion at the beginning of the study and follow-up brain magnetic resonance imaging with magnetic resonance spectroscopy and magnetic resonance perfusion three months later. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03411291
Study type	Observational
Source	Cedars-Sinai Medical Center
Contact
Status	Completed
Phase	N/A
Start date	April 2007
Completion date	September 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05040048` - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn	`NCT03316898` - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease	Phase 1
Withdrawn	`NCT02860065` - CPC-201 Alzheimer's Disease Type Dementia: PET Study	Phase 2
Completed	`NCT01315639` - New Biomarker for Alzheimer's Disease Diagnostic	N/A
Not yet recruiting	`NCT03740178` - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)	Phase 1
Recruiting	`NCT05607615` - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease	Phase 2
Terminated	`NCT03307993` - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease	Phase 1
Recruiting	`NCT02912936` - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease	N/A
Active, not recruiting	`NCT02899091` - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease	Phase 1/Phase 2
Not yet recruiting	`NCT02868905` - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women	N/A
Completed	`NCT02907567` - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease	Phase 1/Phase 2
Completed	`NCT02580305` - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study	Phase 2
Completed	`NCT02516046` - 18F-AV-1451 Autopsy Study	Phase 3
Terminated	`NCT02521558` - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease	N/A
Recruiting	`NCT02247180` - Cognitive Rehabilitation in Alzheimer`s Disease	N/A
Completed	`NCT02256306` - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study	N/A
Completed	`NCT02317523` - Alzheimer's Caregiver Coping: Mental and Physical Health	N/A
Completed	`NCT02260167` - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol	N/A
Terminated	`NCT02220738` - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors	Phase 1
Completed	`NCT01826110` - PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms